APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Regulation FD Disclosure
Item 7.01
|
Regulation FD Disclosure. |
Aptevo Therapeutics Inc. (Aptevo) has prepared investor
presentation materials with information about Aptevo, which it
intends to use as part of investor presentations. A copy of the
investor presentation materials to be used by management for
presentations is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K, including the
attached Exhibit 99.1,is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, whether made before or
after the date hereof, except as expressly set forth by specific
reference in such filing to this Current Report on Form 8-K.
|
Item 8.01 |
Other Events |
On January 5, 2017, Aptevo received a $20.0 million cash payment
from Emergent BioSolutions Inc. (Emergent) to the terms of a
Non-Negotiable Promissory Note from Emergent to Aptevo, dated
July 29, 2016, entered into in connection with the spin-off of
Aptevo from Emergent in August 2016.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
See Exhibit Index attached hereto.
About APTEVO THERAPEUTICS INC. (NASDAQ:APVO)
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)). APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Recent Trading Information
APTEVO THERAPEUTICS INC. (NASDAQ:APVO) closed its last trading session down -0.21 at 2.64 with 114,052 shares trading hands.
